Simulations Plus, Inc. (NASDAQ:SLP – Get Free Report) CRO John Anthony Dibella II sold 1,000 shares of the stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $13.37, for a total transaction of $13,370.00. Following the sale, the executive owned 89,140 shares of the company’s stock, valued at $1,191,801.80. This trade represents a 1.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Simulations Plus Stock Performance
Shares of SLP opened at $14.37 on Friday. Simulations Plus, Inc. has a fifty-two week low of $11.09 and a fifty-two week high of $36.45. The company has a market capitalization of $290.27 million, a price-to-earnings ratio of -4.59 and a beta of 1.19. The firm has a 50-day simple moving average of $12.35 and a 200-day simple moving average of $15.93.
Simulations Plus (NASDAQ:SLP – Get Free Report) last announced its earnings results on Thursday, April 9th. The technology company reported $0.35 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.08. Simulations Plus had a negative net margin of 77.96% and a positive return on equity of 16.21%. The business had revenue of $24.29 million during the quarter, compared to the consensus estimate of $21.66 million. Equities research analysts forecast that Simulations Plus, Inc. will post 1.09 EPS for the current year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on SLP shares. Wall Street Zen downgraded shares of Simulations Plus from a “buy” rating to a “hold” rating in a research note on Saturday, April 4th. TD Cowen cut their price target on shares of Simulations Plus from $19.00 to $16.00 and set a “hold” rating for the company in a report on Friday, April 10th. Citigroup reissued a “market perform” rating on shares of Simulations Plus in a report on Tuesday, January 6th. Finally, Zacks Research cut shares of Simulations Plus from a “strong-buy” rating to a “hold” rating in a report on Monday, February 2nd. Three analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $24.40.
Get Our Latest Report on Simulations Plus
About Simulations Plus
Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.
Further Reading
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.
